Conflombardia – Europa
Territori d’Europa
Tutti gli articoli
www.ema.europa.eu Update as of 3 March 2026This news was updated to accurately reflect the number of medicines with a new active substance recommended for marketing authorisation. In 2022, EMA recommended 89 medicines for marketing authorisation. Of these, 42 had a new active substance...
www.ema.europa.eu 12 new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended 12 medicines for approval at its February 2026 meeting. The committee recommended granting a marketing authorisation for mCombriax (influenza and COVID-19 mRNA vaccine), the first...
www.ema.europa.eu EMA has recommended granting a conditional marketing authorisation in the European Union (EU) for Ojemda (tovorafenib) to treat patients aged 6 months and older with paediatric low-grade glioma (a type of non-cancerous brain tumour). Ojemda can be used when the tumour has...
www.ema.europa.eu The vacancy notice for the next EMA Executive Director has been published in the Official Journal of the European Union, marking the beginning of the recruitment process for the most senior role at the Agency. The next Executive Director will take over the position from...
www.ema.europa.eu CVMP opinions on veterinary medicinal products The Committee adopted a positive opinion for a marketing authorisation for Emepax (maropitant), indicated for the prevention of nausea induced by chemotherapy, for vomiting induced by motion sickness, prevention and for...
www.ema.europa.eu EMA’s safety committee (PRAC) recommended that medicines containing levamisole be withdrawn from the EU market. This follows an EU-wide review which concluded that the benefits of these medicines no longer outweigh their risks for the treatment of parasitic worm infections...